Technological challenges of biomembrane-coated top-down cancer nanotherapy

Cancer nanotherapy suffers from low-yield delivery that is imposed by tumour pathophysiological barriers. Top-down drug delivery strategies, including exosomes and cell membrane-coated particles, can improve safety and efficacy owing to the innate biointerfacial properties of these platforms. Here, we discuss the technological challenges that need to be overcome for their clinical implementation.